Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

A team linked to Harvard Medical School has dosed the first patient in a clinical trial designed to reverse cellular aging in the human eye. The study, called ER-100, uses a gene therapy vector to ...

A groundbreaking human trial of ER-100, a cellular reprogramming therapy, has begun, testing whether damaged eye cells can be rejuvenated and potentially opening a new chapter in the science of aging.

For the first time ever, scientists are attempting to reverse cellular aging in a living patient. The target: incurable vision loss. The risk: cancer.

"Hearst Magazines and AOL may earn commission or revenue on some items through these links." As we age, so do our cells. But some scientists are wondering if we actually need to accept this inevitable ...

Watch a subscriber-only discussion exploring longevity's new focus. Available only for MIT Alumni and subscribers. Listen to the session or watch below Billions of dollars are flooding into efforts to ...

Blindness itself might become, at least in certain cases, partially reversible. This potential future stems from one of the most intriguing developments in regenerative medicine: epigenetic ...

Leafcutter ants live in highly organized colonies where every ant has a job, and now researchers can flip those jobs like a switch. By manipulating just two neuropeptides, scientists can turn ...

Looking ahead to 2030, our model projects OSK could trade at an average price of $158.97, with a potential range between $119.23 and $198.72. This represents a potential 8.6% return from today's price ...